282718-42-7
282718-42-7
Chemical Structure
WX-293
- CAS No.: 282718-42-7
- Formula:C19H27N5O
- Molecular Weight:341.45
InChIKey: YQPLKJCBEOVDBS-UHFFFAOYSA-N
SMILES: O=C(NC12CC3CC(C2)CC(C1)C3)NCC4=CC=C(NC(N)=N)C=C4
Biological Activity: WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
WX-293 | WX-293 is a highly selective urokinase-type plasminogen activator (uPA) inhibitor with a Ki value of 2.4 μM. WX-293 abolishes hypoxia-induced keratinocyte migration and in vitro wound closure. WX-293 can be used in research on hypoxia-mediated skin wounds and solid malignant tumors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Daniel RJ, et al. Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. J Invest Dermatol. 2002;119(6):1304-1309. [Content Brief]
- [2]. Muehlenweg B, et al. Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opin Biol Ther. 2001;1(4):683-691. [Content Brief]
